Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects
Authors:
- Mahmoud HasanMHMahmoud Hasan
- Christiane ModessCMChristiane Modess
- Tarek RoustomTRTarek Roustom
- Anne DokterADAnne Dokter
- Markus GrubeMGMarkus Grube
- Andreas LinkALAndreas Link
- Hélène ReyHRHélène Rey
- Stefanie AdlerSAStefanie Adler
- Konrad MeissnerKMKonrad Meissner
- Werner SiegmundWSWerner Siegmund
- 21 May 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 135 (2) , 326-339
Abstract
Background: The anesthetic ketamine after intravenous dosing is nearly completely metabolized to R- and S-stereoisomers of the active norketamine (analgesic, psychoactive) and 2,6-hydroxynorketamine (potential analgesic, antidepressant) as well as the inactive dehydronorketamine. Oral administration favors the formation of 2,6-hydroxynorketamines via extensive presystemic metabolism. The authors hypothesized that plasma exposure to 2,6-hydroxynorketamines relative to the psychoactive ketamine is greater after prolonged-release ketamine tablets than it is after intravenous ketamine. Methods: Pharmacokinetics of ketamine after intravenous infusion (5.0 mg) and single-dose administrations of 10, 20, 40, and 80 mg prolonged-released tablets were evaluated in 15 healthy white human subjects by means of a controlled, ascending-dose study. The stereoisomers of ketamine and metabolites were quantified in serum and urine by validated tandem mass-spectrometric assays and evaluated by noncompartmental pharmacokinetic analysis. Results: After 40 mg prolonged-release tablets, the mean ± SD area under the concentrations–time curve ratios for 2,6-hydroxynorketamine/ketamine were 18 ± 11 (S-stereoisomers) and 30 ± 16 (R-stereoisomers) compared to 1.7 ± 0.8 and 3.1 ± 1.4 and after intravenous infusion (both P < 0.001). After 10 and 20 mg tablets, the R-ratios were even greater. The distribution volumes at steady state of S- and R-ketamine were 6.6 ± 2.2 and 5.6 ± 2.1 l/kg, terminal half-lives 5.2 ± 3.4 and 6.1 ± 3.1 h, and metabolic clearances 1,620 ± 380 and 1,530 ± 380 ml/min, respectively. Bioavailability of the 40 mg tablets was 15 ± 8 (S-isomer) and 19 ± 10% (R-isomer) and terminal half-life 11 ± 4 and 10 ± 4 h. About 7% of the dose was renally excreted as S-stereoisomers and 17% as R-stereoisomers. Conclusions: Prolonged-release ketamine tablets generate a high systemic exposure to 2,6-hydroxynorketamines and might therefore be an efficient and safer pharmaceutical dosage form for treatment of patients with chronic neuropathic pain compared to intravenous infusion. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:Keywords
This publication has 27 references indexed in Scilit:
- NMDAR inhibition-independent antidepressant actions of ketamine metabolitesNature, 2016
- Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosingEuropean Journal of Clinical Pharmacology, 2015
- What is hydroxynorketamine and what can it bring to neurotherapeutics?Expert Review of Neurotherapeutics, 2014
- Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major DepressionBiological Psychiatry, 2012
- Rifampicin has a Profound Effect on the Pharmacokinetics of Oral S‐Ketamine and Less on Intravenous S‐KetamineBasic & Clinical Pharmacology & Toxicology, 2012
- Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On TrialBiological Psychiatry, 2012
- Stereoselective and regiospecific hydroxylation of ketamine and norketamineXenobiotica, 2012
- Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment‐resistant bipolar depressionBritish Journal of Clinical Pharmacology, 2012
- Exposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by TiclopidineClinical Pharmacology & Therapeutics, 2011
- St John’s wort greatly decreases the plasma concentrations of oral S‐ketamineFundamental & Clinical Pharmacology, 2011